問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Thoracic Medicine

List

171Cases

2023-09-01 - 2029-12-31

Phase III

Active
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    VolrustomigKeytruda Injection

Participate Sites
13Sites

Recruiting13Sites

2018-10-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
11Sites

Recruiting10Sites

Terminated1Sites

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2025-06-01 - 2028-12-31

Phase II

Active
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    Tablet

Participate Sites
10Sites

Recruiting10Sites

2021-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2024-11-01 - 2031-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

  • Condition/Disease

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2014-08-01 - 2020-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-09-15 - 2025-12-31

Phase III

Completed
A randomized, double-blind, double-dummy, parallel grouping, multi-center 24 to 52-week variable length trial designed to evaluate Budesonide, Glycopyrronium, and Formoterol Fumarate metered-dose inhalers (MDI) relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressure MDI, the efficacy and safety of adult and adolescent participants with poor asthma control (KALOS)

  • Condition/Disease

    Adults and adolescents with poor asthma control

  • Test Drug

    BGF MDI

Participate Sites
12Sites

Recruiting12Sites

2017-05-01 - 2020-07-31

Phase III

Active
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

  • Condition/Disease

    Non Small-Cell Lung Cancer (NSCLC)

  • Test Drug

    Durvalumab / Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2009-07-01 - 2010-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-02-01 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

1 2 3 4 5 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB